These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17546486)

  • 21. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.
    Michalets EL; Smith LK; Van Tassel ED
    Ann Pharmacother; 1998; 32(7-8):761-5. PubMed ID: 9681092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microvolt T-wave alternans monitoring in a patient with levofloxacin-induced Torsade de Pointes.
    Sahashi Y; Takasugi N; Naruse G; Kubota T; Nishigaki K; Minatoguchi S
    J Electrocardiol; 2018; 51(1):108-110. PubMed ID: 29126547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    J Am Coll Cardiol; 2020 May; 75(20):2623-2624. PubMed ID: 32283123
    [No Abstract]   [Full Text] [Related]  

  • 24. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
    Altin T; Ozcan O; Turhan S; Ongun Ozdemir A; Akyurek O; Karaoguz R; Guldal M
    Can J Cardiol; 2007 Sep; 23(11):907-8. PubMed ID: 17876386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
    Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation.
    Niedrig D; Maechler S; Hoppe L; Corti N; Kovari H; Russmann S
    Eur J Clin Pharmacol; 2016 Jul; 72(7):859-67. PubMed ID: 27023463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
    Ly T; Ruiz ME
    Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
    Saint-Gerons DM; Tabarés-Seisdedos R
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects].
    van de Loo A; Klingenheben T; Hohnloser SH
    Z Kardiol; 1994 Dec; 83(12):887-90. PubMed ID: 7846927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QT interval prolongation and torsade de pointes associated with indapamide. Comments to Letsas et al.
    Perciaccante A; Fiorentini A
    Int J Cardiol; 2007 Nov; 122(3):255; author reply 256-7. PubMed ID: 17368589
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug induced QT prolongation and torsades de pointes.
    Yap YG; Camm AJ
    Heart; 2003 Nov; 89(11):1363-72. PubMed ID: 14594906
    [No Abstract]   [Full Text] [Related]  

  • 34. Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes.
    Ohara H; Nakamura Y; Watanabe Y; Cao X; Yamazaki Y; Izumi-Nakaseko H; Ando K; Yamazaki H; Yamazaki J; Ikeda T; Sugiyama A
    Cardiovasc Toxicol; 2015 Jul; 15(3):232-40. PubMed ID: 25367413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case-based approach to evaluating azithromycin use and cardiovascular risks.
    Wong E; Nguyen TV
    Consult Pharm; 2014 Jan; 29(1):47-52. PubMed ID: 24413014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adverse drug reactions. QT-prolongation and torsade-de-pointes arrhythmias].
    Haffner S; Lapp H; Thürmann PA
    Dtsch Med Wochenschr; 2002 May; 127(19):1022-4. PubMed ID: 11997870
    [No Abstract]   [Full Text] [Related]  

  • 37. Long QT syndrome and torsade de pointes associated with Takotsubo cardiomyopathy.
    Ahn JH; Park SH; Shin WY; Lee SW; Lee SJ; Jin DK; Lee HM; Eun JY
    J Korean Med Sci; 2011 Jul; 26(7):959-61. PubMed ID: 21738353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia.
    Castillo R; Pedalino RP; El-Sherif N; Turitto G
    Ann Pharmacother; 2002 Jun; 36(6):1006-8. PubMed ID: 12022902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case.
    Wang MH; Tseng CD; Bair SY
    Hum Exp Toxicol; 1998 Oct; 17(10):587-90. PubMed ID: 9821023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QT prolongation and torsades de pointes in a patient with heart block and a pacemaker.
    Bernstein BS; Silver ES; Liberman L
    Cardiol Young; 2016 Jan; 26(1):161-3. PubMed ID: 25599745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.